Business Description
Mesoblast Ltd
NAICS : 541711
ISIN : AU000000MSB8
Share Class Description:
MEOBF: Ordinary SharesCompare
Compare
Traded in other countries / regions
MSB.AustraliaMESO.USALWB.Germany IPO Date
2006-10-31Description
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.63 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.24 | |||||
| Debt-to-EBITDA | -2.52 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0.29 | |||||
| Beneish M-Score | -2.09 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -44.5 | |||||
| 3-Year EBITDA Growth Rate | 14.5 | |||||
| 3-Year EPS without NRI Growth Rate | 6.9 | |||||
| 3-Year FCF Growth Rate | 3.8 | |||||
| 3-Year Book Growth Rate | -12.5 | |||||
| Future 3-5Y Total Revenue Growth Rate | -13.74 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 100 | |||||
| 9-Day RSI | 99.99 | |||||
| 14-Day RSI | 99.85 | |||||
| 6-1 Month Momentum % | -35.25 | |||||
| 12-1 Month Momentum % | -74.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.71 | |||||
| Quick Ratio | 2.71 | |||||
| Cash Ratio | 2.46 | |||||
| Days Sales Outstanding | 120.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.9 | |||||
| Shareholder Yield % | -9.25 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -877.49 | |||||
| Net Margin % | -1072.57 | |||||
| FCF Margin % | -776.71 | |||||
| ROE % | -13.03 | |||||
| ROA % | -9.77 | |||||
| ROIC % | -8.62 | |||||
| ROC (Joel Greenblatt) % | -754.69 | |||||
| ROCE % | -8.31 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 0.09 | |||||
| PE Ratio without NRI | 0.09 | |||||
| PEG Ratio | 0.01 | |||||
| PS Ratio | 62.5 | |||||
| PB Ratio | 1 | |||||
| EV-to-EBIT | -12.06 | |||||
| EV-to-EBITDA | -12.81 | |||||
| EV-to-Revenue | 102.5 | |||||
| EV-to-Forward-Revenue | 17.13 | |||||
| EV-to-FCF | -13 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.01 | |||||
| Earnings Yield (Greenblatt) % | -8.29 | |||||
| FCF Yield % | -8.32 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:MEOBF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mesoblast Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 6.058 | ||
| EPS (TTM) ($) | 5.325 | ||
| Beta | 1.09 | ||
| Volatility % | 157.8 | ||
| 14-Day RSI | 99.85 | ||
| 14-Day ATR ($) | 0.013097 | ||
| 20-Day SMA ($) | 0.46003 | ||
| 12-1 Month Momentum % | -74.27 | ||
| 52-Week Range ($) | 0.1 - 1 | ||
| Shares Outstanding (Mil) | 1,140.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mesoblast Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mesoblast Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mesoblast Ltd Frequently Asked Questions
What is Mesoblast Ltd(MEOBF)'s stock price today?
The current price of MEOBF is $0.60. The 52 week high of MEOBF is $1.00 and 52 week low is $0.10.
When is next earnings date of Mesoblast Ltd(MEOBF)?
The next earnings date of Mesoblast Ltd(MEOBF) is 2024-05-24 Est..
Does Mesoblast Ltd(MEOBF) pay dividends? If so, how much?
Mesoblast Ltd(MEOBF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers